Patient Information Leaflet: Part 1 select-d

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Patient Information Leaflet: Part 1 select-d"

Transcription

1 <To be printed on hospital headed paper> Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This information sheet describes a research study that is taking place at the University of Warwick. Your health care provider is involved with recruiting participants for the study, and giving and monitoring care. The study is called select-d and is comparing two different types of treatment for a blood clot in people who have or have had cancer, and also looks into the ideal length of time to give the treatment for. Invitation It has been confirmed that you have a blood clot (sometimes called a thrombosis). These blood clots are more common in people who have had or are having treatment for cancer. We would therefore like to invite you to take part in this research study. Before you decide whether or not you are willing to participate, we would like to explain why the research is being done and what it will involve. Please take time to read the following information carefully and please feel free to discuss it with friends, relatives and your health care providers. Part 1 (this part) explains the purpose of this study and what will happen to you if you decide to take part. Part 2 provides you with more detailed information about the way the study will be carried out. select-d PIL v2.0; 05-Apr

2 A member of your hospital or community care team will go through this information leaflet with you. Please ask us if there is anything that is not clear or if you would like more information. Please take time to decide whether or not you wish to take part. Please be assured that taking part in this research is entirely voluntary. If you decide not to take part, your medical care will not be affected in any way. What is the purpose of the study? Thrombosis or blood clots are a major problem facing people with cancer. It appears that cancer cells can release chemicals which make the blood thicker than usual and therefore more likely to form a clot. A thrombosis may cause a red, painful, swollen leg or arm (a deep vein thrombosis or DVT) or, if bits of the clot break off and are carried to the lungs, sudden onset of breathlessness, cough or chest pain (a pulmonary embolus or PE). The clots require treatment as some may be life-threatening. Advances have been made in developing new blood thinning treatments to treat blood clots, called anticoagulants. Standard treatment is with a daily injection under the skin of a blood thinning agent called dalteparin or Fragmin which has been shown to have advantages over warfarin in patients with cancer who were treated for 6 months. Dalteparin helps to dissolve the clot and prevent others forming. A new blood thinning agent called rivaroxaban or Xarelto has been used as an alternative to dalteparin in some research studies. Rivaroxaban has the advantage of being a tablet rather than an injection. Whether to stop or continue anticoagulation after 6 months, however, remains uncertain with no previous research studies having assessed this question in cancer patients to date. More research is needed on the effectiveness of rivaroxaban as it is not yet known whether dalteparin or rivaroxaban is better at treating and preventing clots in people with cancer or for how long the drugs should be taken (6 months or 12 months). The purpose of the study is to find out whether rivaroxaban is as good as dalteparin at treating clots and preventing other clots from forming, and whether it is better to give anticoagulant treatment for 6 or 12 months. select-d PIL v2.0; 05-Apr

3 Why have I been invited? You have been invited to take part as you have cancer, or have had cancer in the past, and now have a blood clot. Do I have to take part? No. It is entirely up to you to decide whether or not to take part. If you do, you will be asked to sign a consent form. If you later change your mind about participating, you will be free to withdraw at any time and without giving a reason. If you decide not to take part, or if after joining the study you decide to withdraw, the standard of care you receive will not be affected. What will happen to me if I take part? All people who choose to take part in the study will be allocated their anticoagulant drug randomly (by chance) - we call this randomisation. The study will involve an initial 6 months treatment and then (for the majority of people but only if indicated) a further six months of treatment. Both treatments will be allocated by randomisation using a computer. You have an equal chance of receiving either treatment at each randomisation but you will not be able to choose. Your treatment will be randomly assigned to you by the Study Coordinating Centre at the University of Warwick. First Randomisation: The initial treatment will be: Group 1 Dalteparin injections given just under the skin (standard therapy in the UK). The injections will be given by yourself, a member of your family, a carer or a district nurse. or Group 2 Rivaroxaban tablets (research study therapy). Standard (non-trial) treatment would usually stop at six months after the onset of a blood clot. However, if you join the study, and have a DVT, you will have an ultrasound scan of the area around your DVT at about five months to see whether the blood clot has completely dispersed or if there is any of it left (known as residual vein thrombosis ). If the clot has select-d PIL v2.0; 05-Apr

4 completely dispersed you will have no further treatment. However, if the scan indicates that the clot has not completely gone, or if you initially had a pulmonary embolism, you will be allocated by random, to a further six months of the tablet anticoagulant or a placebo (dummy) tablet. This is because we are hoping to find out whether the potential benefit of further anticoagulant treatment outweighs the potential side-effects. Longer treatments may have the benefit of giving more drug to the clot but they have the disadvantage of causing more treatment side effects. In this case, the most serious side effect is bleeding, which is discussed later in this leaflet. Second Randomisation: The second treatment will be: Group 1 Placebo (a dummy tablet that has no activity) or Group 2 Rivaroxaban (study tablets) Studies that have placebo treatments are necessary to produce the most reliable results about the treatment and whether longer or shorter anticoagulation therapy is more beneficial. It is important that neither you or your doctor or your research nurse knows which type of tablet you are taking so that information recorded within the trial is not influenced by this knowledge. However, this information can be found out by your doctor if there is an important clinical reason to do so. Information about your progress will be collected for two years. Part of the research is to compare whether either treatment has an impact on your quality of life (general wellbeing). To assess this, you will be asked to fill in questionnaires at certain intervals (before your treatment starts, every 3 months for the first year and then at 18 months and 24 months after the onset of the clot). We will also ask you to complete questionnaires about whether the disease and its treatment affect your finances. This is to monitor and identify any financial burden to participants and their families caused by either of the treatments given in this study. The research team will also record your progress in your hospital/gp notes during routine clinic visits. select-d PIL v2.0; 05-Apr

5 At the start of the study, at 3 months, at 6 months and, if your treatment continues for a year, at 12 months, you will be also have an additional research blood sample taken from you. This will be used to add to a large databank of information that may be used by researchers to find out about cancer in the future. You will also be asked if we can keep any pieces of any tissue or cancer that may have been removed during your initial cancer surgery (if you had this). These are called tissue samples and may be used for future research. There are strict rules about keeping tissue samples. You can still take part in the study even if you do not want us to use your blood and tissue samples. More information about sample collection is given in Part 2. Expenses and payments We are unable to pay you for taking part in the research. You may incur some minor expenses if you take part, such as the cost of car parking for more frequent hospital visits. We will try and keep these to an absolute minimum and we will reimburse you for any additional travel expenses, if requested. What will I have to do? If you agree to take part, you will be asked to attend your scheduled visits (treatment and follow-up) which may be more frequent than if you are not on the study. You will also be asked to give an extra blood sample on 3 or 4 occasions and you will be asked to fill in some questionnaires to monitor your well-being and any financial implications of the study on 7 occasions. If you have a DVT, you will also need to have an additional ultrasound scan to see if you need to continue treatment for longer than 6 months. What are the potential disadvantages and risks of taking part? You will be asked to complete questionnaires which will take some time over and above your usual hospital/gp visits. The additional blood samples will be taken when you have standard blood tests and therefore should not cause you any additional discomfort. select-d PIL v2.0; 05-Apr

6 Before participating in the research, you should consider if your participation will affect any insurance you may have and seek advice if necessary. There are certain side-effects to the drugs used in the study (although these will be the same if you are received drugs as standard treatment not in a trial). These are detailed below: Side-effects of treatment The side-effects of dalteparin and rivaroxaban are similar and the most serious is unusual or excessive bleeding or bruising. You will be given details of what to look out for and who to contact if you have any side-effects when you receive your treatment. However, if you have any bleeding that will not stop or is not normal for you (for example, a severe nose bleed or blood when you cough or go to the toilet) you must inform your doctor or nurse immediately. Participants who receive dalteparin may also experience discomfort at the injection sites. Possible risks to the unborn child The risks of anti-coagulant therapy on the unborn child are not fully known. It is therefore strongly advised that all people taking anticoagulants in the select-d trial use a reliable method of contraception during treatment and for six months afterwards, if they or their partner has the potential to conceive a baby. If you think you or your partner may be pregnant, you must inform your doctor or nurse immediately. Reliable methods of contraception include hormonal methods, such as the pill or implant, coils and condoms or caps with spermicide. Please speak to your doctor or nurse if you have any questions or concerns about this. What are the possible benefits of taking part? We cannot tell if the study will help you personally but the information we get from this study may help to improve the treatment of people with cancer in the future. select-d PIL v2.0; 05-Apr

7 What if there is a problem? Any complaint you have will be addressed. More information will be given to you later in this document. What happens if I don t want to carry on with the study? If you withdraw or are unable to continue the study for any reason, we will only use the information that you have already given us to that point, unless you ask us to remove all your information (this may include your blood and tissue samples and questionnaires, if you wish). You may be asked to sign an additional form to confirm your wishes. Will my taking part in this study be kept confidential? Yes. All the information about your participation in this study will be kept confidential. The details are included in Part 2. Contacts for further information Your local contact for the study is: [INSERT NAME] [INSERT CONTACT DETAILS] Local Researcher: [Insert name and contact details of local investigator] Further information about research and about your type of cancer can be found at: This completes Part 1 of the Information Leaflet. If the information in Part 1 has interested you and you are considering participation, please continue to read the additional information in Part 2 before making your decision. select-d PIL v2.0; 05-Apr

8 Patient Information Leaflet: Part 2 select-d Anticoagulation Therapy in SELECTeD Cancer Participants at Risk of Recurrence of Venous Thromboembolism What if new information becomes available about clot treatment while I am on the trial? Sometimes we get new information about the treatment being studied. If this happens, your doctor will discuss this with you and decide whether or not you should continue in the study. If you decide not to continue, your doctor will make arrangements for your future care. If you do continue in the study, you may be asked to read a new Information leaflet and sign a new consent form. In the unlikely event of the study stopping before the end of your treatment, you will be treated according to the usual procedures at your hospital and in consultation with your doctor. Your progress will be followed in the same way as discussed earlier. What if there is a problem? If you are unsatisfied with the treatment that you receive by any member of staff (doctor, nurse etc.) you have the same rights as any NHS patient to voice and register your complaints through the hospital complaints procedure. If you have a complaint in relation to the study, you can contact the University of Warwick Deputy Registrar, Ms Joanna Horsburgh, by telephone: +44 (0) , or at: Ms J Horsburgh, Deputy Registrar s Office, University of Warwick, Coventry, CV4 8UW, United Kingdom. If you wish to complain formally, you can do this through the NHS Complaints Procedure. The person to be contacted for this is [Insert local complaints manager contact details]. In the event that something does go wrong and you are harmed during the research due to someone s negligence then you may have grounds for a legal action for compensation but you may have to pay your own legal costs. select-d PIL v2.0; 05-Apr

9 Will information about me be kept confidential? Yes; we will follow professional, ethical and legal practice and all information which is collected about you during the course of the research will be kept strictly confidential. Information held by the NHS (such as your hospital number and date of birth) and records maintained by the General Register Office may be used to follow your health status. Any information about you which leaves the hospital will have your name and address removed so that you cannot be identified. Data collected for the study will be coded and the Chief Investigator will act as custodian of the data and regulate access. Authorised persons (e.g. representatives from the Sponsor, regulatory authorities and Research & Development departments) may need to look at information collected about you, including your medical notes. Confidentiality will be maintained at all times. With your permission, your GP will be notified that you are taking part in this study. He/she will be provided with a copy of this Patient Information Leaflet. What will happen to any samples I give? As mentioned in Part 1, we will request blood and tissue samples from you. If you give consent for us to collect these, they will be stored and used for future research about cancer which may take place within or outside the UK. The information attached to these samples will never include your name or address or any information that can identify you personally. Will any genetic tests be done on any of the samples I give? If you give consent for your blood and tissue samples to be used for other research projects they may include genetic tests. These studies will be approved by an ethics committee now or in the future before any blood or tissue is used. The genetic tests will not predict your personal risk of inheritance and they will have no effect on your insurance or other financial risks. The tests are usually those that help us understand how cancers and blood clots develop and how we can diagnose and treat them better. You can refuse to have your samples used in this way if you wish, without it affecting your participation in the study. select-d PIL v2.0; 05-Apr

10 What will happen to the results of the research study? The results of the research will be published in scientific journals over the next few years. You will not be identified in person in any report or publication arising out of this study. If you wish, you can request a summary of the main results of the study when available. We will keep your health care provider informed of the study progress and they will be pleased to let you or your family know about the study outcome if you would like. Who is organising and funding the research? The research is being co-ordinated by the Warwick Clinical Trials Unit, based at the University of Warwick. The University of Warwick is the Sponsor for this study. The study is funded by Bayer plc. Who has reviewed the study? The study has been reviewed and given a favourable opinion by the West Midlands Coventry and Warwickshire Ethics Committee and the Medicines and Healthcare Products Regulatory Agency (MHRA). We have also worked with patient representatives who have regularly reviewed the study protocol and will continue to work with us throughout the study. What to do if you wish to take part in the study? If you wish to participate in this study you will be asked to sign a consent form after discussion with the researcher. You will also be given a copy of this information leaflet and a signed copy of the consent form to keep. If you decide that you do not want to take part, it will have no effect on any treatment or care that you will receive. Thank you for taking time to read this information leaflet and for considering the study. select-d PIL v2.0; 05-Apr

The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial of treatment after surgery for prostate cancer

The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial of treatment after surgery for prostate cancer Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire HP21 8AL Tel: 01296 315 908 www.buckshealthcare.nhs.uk The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial

More information

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast Information for patients Pharmacy Your doctor has prescribed a tablet called rivaroxaban. This leaflet tells you about

More information

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Oxford University Hospitals NHS Trust Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for people with a blood clot (thrombus) What is this

More information

PATIENT INFORMATION SHEET

PATIENT INFORMATION SHEET PATIENT INFORMATION SHEET Surgical and large bore pleural procedures in Malignant pleural Mesothelioma And Radiotherapy Trial (SMART trial) Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire

More information

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included. These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily

More information

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has

More information

Confirmed Deep Vein Thrombosis (DVT)

Confirmed Deep Vein Thrombosis (DVT) Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or

More information

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT

A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk

More information

Community Deep Vein Thrombosis (DVT)Service

Community Deep Vein Thrombosis (DVT)Service Community Deep Vein Thrombosis (DVT)Service Patient information guide Telephone: 01225 474273 Your scan will take place at: Combe down Branch Surgery Sulis Manor Rd Odd Down Bath BA2 2AL Date:. Time:.

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet

More information

Deep Vein Thrombosis (DVT)

Deep Vein Thrombosis (DVT) Patient Information Service Bristol Royal Infirmary Deep Vein Thrombosis (DVT) Thrombosis Clinic 0117 342 4684 Respecting everyone Embracing change Recognising success Working together Our hospitals. This

More information

Taking Part in Research at University Hospitals Birmingham

Taking Part in Research at University Hospitals Birmingham University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121

More information

A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT

A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to

More information

A patient's guide. Your clinic's contact details are: Name: Contact number:

A patient's guide. Your clinic's contact details are: Name: Contact number: A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose

More information

Deep Vein Thrombosis (DVT) in pregnancy

Deep Vein Thrombosis (DVT) in pregnancy Deep Vein Thrombosis (DVT) in pregnancy Information and advice for women and families Maternity What is a deep vein thrombosis (DVT)? A deep vein thrombosis (DVT) is a blood clot that forms in a deep leg

More information

Reducing the risk of a blood clot for patients with plaster casts Information for patients

Reducing the risk of a blood clot for patients with plaster casts Information for patients Oxford University Hospitals NHS Trust Reducing the risk of a blood clot for patients with plaster casts Information for patients page 2 What is this leaflet for? When you have your leg held in a certain

More information

Rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) Rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) This leaflet aims to answer your questions about rivaroxaban that may be prescribed for you when you are diagnosed

More information

Preventing Blood Clots in Adult Patients. Information For Patients

Preventing Blood Clots in Adult Patients. Information For Patients Preventing Blood Clots in Adult Patients Information For Patients 1 This leaflet will give you information on how to reduce the risk of developing blood clots during and after your stay in hospital. If

More information

Information for patients who require Foam Sclerotherapy for Varicose Veins.

Information for patients who require Foam Sclerotherapy for Varicose Veins. Information for patients who require Foam Sclerotherapy for Varicose Veins. Why do I need this procedure? Everybody has two sets of veins in the legs. These include the superficial and deep veins. Their

More information

Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?

Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy? Information for you Treatment of venous thrombosis in pregnancy and after birth Published in September 2011 What is venous thrombosis? Thrombosis is a blood clot in a blood vessel (a vein or an artery).

More information

Deep Vein Thrombosis (DVT) and Warfarin

Deep Vein Thrombosis (DVT) and Warfarin Deep Vein Thrombosis (DVT) and Warfarin A guide to your diagnosis and treatment Information for patients, relatives and carers Anticoagulant Clinic Tel: 01904 726785 The York Hospital, Wigginton Road,

More information

A Guide to Clinical Trials

A Guide to Clinical Trials A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.

More information

The ACCURE-UK Trial: The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis

The ACCURE-UK Trial: The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis The ACCURE-UK Trial: The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis Patient Research Interview Information Sheet ACCURE-UK non-participants Version

More information

Participant Information Sheet/Consent Form. Norfolk & Norwich University Hospital NHS Foundation Trust. Marc Moncrieff

Participant Information Sheet/Consent Form. Norfolk & Norwich University Hospital NHS Foundation Trust. Marc Moncrieff Participant Information Sheet/Consent Form Norfolk & Norwich University Hospital NHS Foundation Trust Short Title The Melanoma Margins Trial (MelMarT) Title A Phase III, Multi-centre Randomised Control

More information

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function.

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function. Version 2. 8.09.2011 Hammersmith Hospital Du Cane Rd London W12 0HS Tel: 020 8383 1000 www.imperial.nhs.uk PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric

More information

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) 2011 Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) We have written this pamphlet to help you learn about deep vein thrombosis and pulmonary

More information

Safety Information Card for Xarelto Patients

Safety Information Card for Xarelto Patients Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist

More information

abortion your questions answered

abortion your questions answered abortion your questions answered About Marie Stopes International Marie Stopes International is a specialist reproductive healthcare organisation and a registered charity working in both the UK and overseas.

More information

U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet

U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet 1. Invitation You are being invited to take part in a research study. Before you decide it is important for you

More information

Rivaroxaban (Xarelto) for preventing blood clots after hip or knee replacement surgery

Rivaroxaban (Xarelto) for preventing blood clots after hip or knee replacement surgery medicineupdate Asking the right questions about new medicines Rivaroxaban (Xarelto) for preventing blood clots after hip or knee replacement surgery This Medicine Update is for people who have been prescribed

More information

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs? Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood

More information

ADVICE ON TRAVEL-RELATED DEEP VEIN THROMBOSIS

ADVICE ON TRAVEL-RELATED DEEP VEIN THROMBOSIS ADVICE ON TRAVEL-RELATED DEEP VEIN THROMBOSIS Introduction 1. A possible link between deep vein thrombosis (DVT) and long haul air travel was first suggested by reports in medical journals in the 1950s.

More information

Participant Invitation and Information Sheet MRI Test Run

Participant Invitation and Information Sheet MRI Test Run ON QE TRUST HEADED PAPER A randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial

More information

Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients

Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients Horton General Hospital Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Information for patients What is a Deep Vein Thrombosis (DVT)? A DVT is a blood clot which forms in a deep vein, usually in

More information

Local Steroid Injections to Joints and Soft Tissues. Rheumatology Patient Information Leaflet

Local Steroid Injections to Joints and Soft Tissues. Rheumatology Patient Information Leaflet Local Steroid Injections to Joints and Soft Tissues Rheumatology Patient Information Leaflet Welcome to The Dudley Group Rheumatology department. This leaflet will provide you with information about what

More information

PATIENT INFORMATION SHEET KEY FACTS

PATIENT INFORMATION SHEET KEY FACTS PATIENT INFORMATION SHEET KEY FACTS Please read this carefully and refer to the full information sheet You are invited to take part in a research study, comparing subcutaneously (injection under skin)

More information

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)

More information

DEEP VEIN THROMBOSIS. James St.George, M.D., RPVI, RVT, RPhS

DEEP VEIN THROMBOSIS. James St.George, M.D., RPVI, RVT, RPhS DEEP VEIN THROMBOSIS James St.George, M.D., RPVI, RVT, RPhS Originally Published In Florida Times Union March 2014 James St.George, M.D., RPVI, RVT, RPhS Dr. St. George is the Medical Director of St Johns

More information

Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban

Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban Venous Thrombosis and Pulmonary Embolism Treatment with Rivaroxaban Information for patients and families Read this booklet to learn: about venous thrombosis and pulmonary embolism how the medicine Rivaroxaban

More information

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip A Review of the Research for Adults Is This Information Right for Me? Yes, if: You are considering or planning to

More information

Ultrasound-guided steroid injections in joints and soft tissues. Rheumatology Patient Information Leaflet

Ultrasound-guided steroid injections in joints and soft tissues. Rheumatology Patient Information Leaflet Ultrasound-guided steroid injections in joints and soft tissues Rheumatology Patient Information Leaflet Welcome to The Dudley Group Rheumatology department. This leaflet will provide you with information

More information

Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES. Sponsored by Cardiff University

Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES. Sponsored by Cardiff University Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES Sponsored by Cardiff University Chief Investigator Wales: Professor Colin Dayan Address: Centre

More information

Your Guide to Preventing and Treating Blood Clots

Your Guide to Preventing and Treating Blood Clots Your Guide to Preventing and Treating Blood Clots U.S. Department of Health and Human Services Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 AHRQ Pub. No. 09 0067 C May

More information

Suspected pulmonary embolism (PE) in pregnant women

Suspected pulmonary embolism (PE) in pregnant women Suspected pulmonary embolism (PE) in pregnant women What is a pulmonary embolus? A deep vein thrombosis (DVT) is a blood clot that forms in one of the deep veins of the leg. If the clot moves to the lung,

More information

Inferior Vena Cava filter and removal

Inferior Vena Cava filter and removal Inferior Vena Cava filter and removal What is Inferior Vena Cava Filter Placement and Removal? An inferior vena cava filter placement procedure involves an interventional radiologist (a specialist doctor)

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Deep Vein Thrombosis or Pulmonary Embolism

Deep Vein Thrombosis or Pulmonary Embolism What You Need to Know After Deep Vein Thrombosis or Pulmonary Embolism The content provided here is for informational purposes only. It is not intended to diagnose or treat a health problem or disease,

More information

Hysterectomy for womb cancer

Hysterectomy for womb cancer Gynaecology Oncology Service Hysterectomy for womb cancer April 2014 Great Staff Great Care Great Future INTRODUCTION This leaflet has been produced to provide you with general information about your operation.

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has

More information

What Is Deep Vein Thrombosis?

What Is Deep Vein Thrombosis? Page 1 of 8 For more information, visit http://www.nhlbi.nih.gov/health/health-topics/topics/dvt/ What Is Deep Vein Thrombosis? Deep vein thrombosis (throm-bo-sis), or DVT, is a blood clot that forms in

More information

Breast Cancer in the Family

Breast Cancer in the Family Oxford University Hospitals NHS Trust Oxford Regional Genetic Department Breast Cancer in the Family Information for women with a moderately increased risk of breast cancer Breast cancer in the family

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Long term observational study for multiple sclerosis patients using fingolimod

Long term observational study for multiple sclerosis patients using fingolimod Investigator: Dr Matthew Jackson (Consultant Neurologist) Centre number: 814 Contact for queries If you have any questions about this study, you can contact: Daytime: Elspeth Wolfenden on 01494 734312

More information

A PATIENT GUIDE TO HOME USE CLEXANE (ENOXAPARIN)

A PATIENT GUIDE TO HOME USE CLEXANE (ENOXAPARIN) A PATIENT GUIDE TO HOME USE CLEXANE (ENOXAPARIN) Patient Information Leaflet Your Health. Our Priority. Page 2 of 5 What Is Clexane? CLEXANE helps to reduce the risk of blood clots and is known as an anticoagulant

More information

Giving Yourself Dalteparin (Fragmin) or Heparin

Giving Yourself Dalteparin (Fragmin) or Heparin Contents www.bcwomens.ca What is Dalteparin (Fragmin)...1 Where do I get this medication from?...1 How often do I give myself this medication?...1 Side effects...1 Steps to Giving Yourself Dalteparin (Fragmin)..1

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials The UK Clinical Research Collaboration (UKCRC) is a partnership of organisations working to establish the UK as a world leader in clinical research, by harnessing the power

More information

Prothrombin Gene Mutation

Prothrombin Gene Mutation Information for patients and families \ What is prothrombin gene mutation? Prothrombin gene mutation is a blood clotting disorder, not a disease. It causes the body to make too much prothrombin, which

More information

Information for Egg Donors for Research

Information for Egg Donors for Research Newcastle Fertility Centre at BioScience Centre, International Centre for Life Times Square, Newcastle upon Tyne, NE1 4EP Telephone: 0191 2138213 Fax: 0191 2138124 www.nfc-life.org.uk Information for Egg

More information

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs

More information

DT- PACE chemotherapy for myeloma

DT- PACE chemotherapy for myeloma Patient information DT- PACE chemotherapy for myeloma Your doctors have suggested that you are likely to benefit from chemotherapy treatment. They are recommending a standard form of treatment called DT-PACE

More information

Information about the research

Information about the research Information about the research Health beliefs in OCD participants with OCD information sheet (non-nhs participants version) We would like to invite you to take part in our research study. The study is

More information

Breast cancer in the family

Breast cancer in the family Birmingham Women's NHS Foundation Trust Breast cancer in the family Information for women with a slightly increased risk of breast cancer This is a no smoking hospital Breast cancer in the family what

More information

XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS

XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS XARELTO BLEEDING RISKS AND POTENTIALLY FATAL SIDE EFFECTS 1 In 2011, a new anticoagulant drug was approved by the U.S. Food and Drug Administration (FDA). The new drug Xarelto was marketed as a more convenient

More information

Radioactive Ra 223 therapy. Information for patients Weston Park Hospital

Radioactive Ra 223 therapy. Information for patients Weston Park Hospital Radioactive Ra 223 therapy Information for patients Weston Park Hospital page 2 of 8 This leaflet contains information about radioactive Ra 223 therapy. If you have any questions about your treatment,

More information

Information for you Abortion care

Information for you Abortion care Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect

More information

Catheter insertion of a new aortic valve to treat aortic stenosis

Catheter insertion of a new aortic valve to treat aortic stenosis Issue date March 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical

More information

SUPRAPUBIC CATHETER INSERTION INFORMATION FOR PATIENTS

SUPRAPUBIC CATHETER INSERTION INFORMATION FOR PATIENTS The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk INFORMATION

More information

Research Ethics Review Committee (WHO ERC)

Research Ethics Review Committee (WHO ERC) Research Ethics Review Committee (WHO ERC) 20, AVENUE APPIA CH-1211 GENEVA 27 SWITZERLAND HTTP://INTRANET.WHO.INT/HOMES/RPC/ERC HTTP://WWW.WHO.INT/RPC/RESEARCH_ETHICS Informed Consent Template for Clinical

More information

Phasel clinical trials:

Phasel clinical trials: Phasel clinical trials: what are they all about? Information for people wanting to know more about early clinical trials in cancer, Belfast City Hospital NORTHERN IRELAND CANCER TRIALS CENTRE Introduction

More information

Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet

Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet Study Title: Family Focused Therapy for Bipolar Disorder: A Clinical Case Series) We would like to invite

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas

More information

Sample Consent. Transfusion of Prematures (TOP)

Sample Consent. Transfusion of Prematures (TOP) Final: October 8. 2012 Revised: February 8. 2013 Appendix A: Sample Consent ~ Penn Medicine,~. Informed Consent Form and HIPAA Authorization Protocol Title: Short Title: Principal Investigator: Emergency

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all

More information

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa)

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa) MEDICATION GUIDE PROCRIT (PROKRIT) (epoetin alfa) Read this Medication Guide: before you start PROCRIT. if you are told by your healthcare provider that there is new information about PROCRIT. if you are

More information

Medical Research. General Information for Research Participants

Medical Research. General Information for Research Participants Medical Research General Information for Research Participants Contents Introduction 5 Medical research 6 What is a medical research? Who is classified as a research participant? Who conducts the research?

More information

Tunnelled indwelling pleural catheter (TIPC)

Tunnelled indwelling pleural catheter (TIPC) Tunnelled indwelling pleural catheter (TIPC) A patient s guide 1 What is a tunnelled indwelling pleural catheter? A tunnelled indwelling pleural catheter is a specially designed small tube to drain fluid

More information

Information about research

Information about research Information about research Welcome to Papworth Hospital a focus on research As a specialist centre we pride ourselves on the quality of care that we provide for our patients. Knowledge in health care

More information

Information about the research

Information about the research Information about the research Health beliefs in OCD participants with OCD information sheet (Non-qualitative interview version) We would like to invite you to take part in our research study. The study

More information

If you are signing for a minor child, you refers to your child throughout the consent document.

If you are signing for a minor child, you refers to your child throughout the consent document. CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight

More information

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2. Background This indication of rivaroxaban had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the

More information

PATIENT INFORMATION SHEET. Version 5, March 2015

PATIENT INFORMATION SHEET. Version 5, March 2015 King s College Hospital NHS Foundation Trust King s College Hospital Denmark Hill London SE5 9RS Tel: 020 3299 9000 Fax: 020 3299 3445 www.kch.nhs.uk PATIENT INFORMATION SHEET Version 5, March 2015 Study

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs

More information

Birth after Caesarean Choices for delivery

Birth after Caesarean Choices for delivery Birth after Caesarean Choices for delivery page 2 What are my choices for birth after a Caesarean? Currently, approximately 1 in 4 women (25%) in England give birth by Caesarean delivery. Some women have

More information

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab) Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety

More information

PARTICIPANT INFORMATION

PARTICIPANT INFORMATION PARTICIPANT INFORMATION IMPERIAL POPULATION BIORESOURCE TISSUE BANK (PART OF NIHR BIORESOURCE) In the UK around 20 million people are said to be living with a long-term condition such as diabetes or heart

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis

More information

Medication Information. (Ri va rox xa - ban)

Medication Information. (Ri va rox xa - ban) Medication Information (Ri va rox xa - ban) Other names for this medication are: Xarelto What does this medication do? This medication is a blood thinner, also called an anticoagulant. It prevents a blood

More information

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions

More information

RESEARCH PARTICIPANT INFORMATION SHEET. Safer pre-natal diagnosis using free DNA in maternal blood test. (also known as the IONA Study)

RESEARCH PARTICIPANT INFORMATION SHEET. Safer pre-natal diagnosis using free DNA in maternal blood test. (also known as the IONA Study) RESEARCH PARTICIPANT INFORMATION SHEET Safer pre-natal diagnosis using free DNA in maternal blood test (also known as the IONA Study) REC ref: 07/H0607/101 Principal Investigator: Mr Edward Johnstone Version

More information

BREAST CANCER TREATMENT

BREAST CANCER TREATMENT BREAST CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre December 2014 Contents About this booklet 1 Your First Oncology Consultation

More information

A guide to prostate cancer clinical trials

A guide to prostate cancer clinical trials 1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part

More information

The University of Texas Southwestern Medical Center at Dallas Retina Foundation of the Southwest CONSENT TO PARTICIPATE IN RESEARCH

The University of Texas Southwestern Medical Center at Dallas Retina Foundation of the Southwest CONSENT TO PARTICIPATE IN RESEARCH The University of Texas Southwestern Medical Center at Dallas Retina Foundation of the Southwest CONSENT TO PARTICIPATE IN RESEARCH Title of Research: Funding Agency/Sponsor: Study Doctors: Research Personnel:

More information

A Patient s Guide to Antithrombotic and Thrombolytic Therapy

A Patient s Guide to Antithrombotic and Thrombolytic Therapy A Patient s Guide to Antithrombotic and Thrombolytic Therapy PATIENT EDUCATION GUIDE What is a blood clot? A blood clot is a solid mass consisting of blood cells and other material that forms inside a

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information